Nyxoah S.A.
NASDAQ:NYXHMedical - Instruments & Supplies
Healthcare
$0.86 +1.25%
+$0.02 today
- Market cap
- $87.45M
- Beta
- 0.89
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$1.99
52W Low $1.26High $8.59
Volume 0.09M
Average 0.22M
Income Statement
Follow revenue through to earnings.
Revenue
$10.02M
FY 2025 · Annual
+121.6% YoYOperating Income
-$82.94M
FY 2025 · Annual
Net Income
-$90.08M
FY 2025 · Annual
Income Statement
EUR
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 852K | 3.08M | 4.35M | 4.52M | 10.02M |
| Cost of Revenue | 303K | 1.15M | 1.66M | 1.55M | 3.69M |
| Gross Profit | 549K | 1.93M | 2.69M | 2.97M | 6.33M |
| Gross Margin | 64.4% | 62.7% | 61.9% | 65.7% | 63.1% |
| Research & Development | 5.95M | 15.86M | 27.66M | 34.33M | 42.82M |
| Selling, General & Admin | 11.11M | 18.86M | 20.65M | 28.46M | 46.44M |
| Operating Expenses | 26.79M | 34.43M | 47.79M | 61.78M | 89.27M |
| Depreciation & Amortization | 1.66M | 1.93M | 2.36M | 764K | 4.48M |
| EBITDA | (22.59M) | (27.89M) | (42.08M) | (53.77M) | (82.9M) |
| EBITDA Margin | -2651.5% | -904.2% | -967.8% | -1189.2% | -827.4% |
| Operating Income | (26.24M) | (32.5M) | (45.1M) | (58.81M) | (82.94M) |
| Operating Margin | -3080.0% | -1053.8% | -1037.3% | -1300.8% | -827.8% |
| Interest Income | 1K | 372K | 2.57M | 2.5M | 1.83M |
| Interest Expense | 386K | 237K | 1.21M | 1.9M | 1.69M |
| Other Income / Expenses | 1.6M | 2.44M | 445K | 2.38M | (6.13M) |
| Income Before Tax | (24.64M) | (30.06M) | (44.66M) | (56.43M) | (89.08M) |
| Pre-Tax Margin | -2891.9% | -974.6% | -1027.1% | -1248.2% | -889.0% |
| Income Tax Expense | 2.98M | 1.17M | (1.45M) | 2.8M | 1.01M |
| Net Income | (27.62M) | (31.23M) | (43.21M) | (59.24M) | (90.09M) |
| Net Margin | -3241.7% | -1012.5% | -993.8% | -1310.2% | -899.1% |
| EPS (Basic) | (1.16) | (1.21) | (1.55) | (1.81) | (2.37) |
| EPS (Diluted) | (1.16) | (1.21) | (1.55) | (1.81) | (2.37) |
| 23.79M | 25.82M | 27.97M | 32.74M | 38.11M | |
| 23.79M | 25.82M | 27.97M | 32.74M | 38.11M |
NYXH Earnings Waterfall · TTM
NASDAQ:NYXH · Revenue to Net Income
Key Ratios
EPS$-2.14
Gross Margin54.6%
Net Margin-850.1%
P/E Ratio-1.9
P/S Ratio73.6
Analysis
$16.3M of revenue converted into -$86.1M of net income for the selected period. Gross margin is 54.6% and net margin is -850.1%, showing how much revenue survives after costs and taxes. EPS is $-2.14, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 5, 2026 | |
| 6-K | 6-K filing | Oct 20, 2026 | |
| 6-K | 6-K filing | Sep 29, 2026 | |
| 6-K | 6-K filing | Sep 22, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
How much revenue does NYXH generate?
Nyxoah S.A. (NYXH) reported $10.02M of revenue in fiscal 2025.
Is NYXH profitable?
Nyxoah S.A. (NYXH) reported -$90.08M of net income, with a net margin of -899.1%.
Continue the stock analysis
Jump to another research area for this company.